We observed relatively high concordance rates using the Illumina NGS platform for genes frequently aberrant in breast cancers e.g., 90.1% (95% CI: 86.8–93.3) for MYC, 63.8% (95% CI: 61.4–66.2) for CCND1 and 57.4% (95% CI: 52.3–62.5) for ERBB2 whilst the corresponding values for the same genes were 29.5% (95% CI: 27.5–31.8), 40.2% (95% CI: 37.7–42.7) and 28.3% (95% CI: 25.6–30.9), respectively, using the Ion Torrent sequencing platform. This evidence concerns the gene CCND1 and breast carcinoma.